Concurrent Chemoradiotherapy with Extended Nodal Irradiation and/or Erlotinib in Locally Advanced Esophageal Squamous Cell Cancer: Long-Term Follow-Up of a Randomized Phase 3 Trial
Congying Xie(Wenzhou Medical University), Shixiu Wu(Fujian Medical University), Lvhua Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruifei Xie(Hangzhou Cancer Hospital), Duojie Li(First Affiliated Hospital of Bengbu Medical College), Ni Zhang(Guiyang Medical University), Hongyan Zhang(Third People's Hospital of Hangzhou), Ming Chen(First Affiliated Hospital Zhejiang University), Bing Xia(Rutgers, The State University of New Jersey), Jing Zhao(Hangzhou Cancer Hospital), Conghua Xie(Wuhan University), Lingyu Ding(Hangzhou Cancer Hospital), Honglei Luo(Huaian First People’s Hospital), Wei Hu(University of Manchester), Anping Zheng(Anyang Tumor Hospital), Xilong Lian(Kaohsiung Medical University), Xiuhua Bian(Jiangsu Cancer Hospital), Dexi Du(Lishui Central Hospital), Qing Liu(Tongji University), Bangxian Tan(Affiliated Hospital of North Sichuan Medical College)
Cited by 0
Related Papers
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
|JAMA Oncology|2020|1.1k
A recurrent mutation in PALB2 in Finnish cancer families
|Nature|2007|461
Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2024|291
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|2022|267
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217